Increased risk of Venous Thrombosis in XXY/KS further exacerbated by testosterone therapy

This study demonstrates poor awareness of the known VTE risks in KS and the potential VTE risks of TT within this cohort. Patients not informed of the inherent risks associated with their condition may be less vigilant to complications, unaware of lifestyle decisions affecting risks, and not able to make informed decisions about medical care. Further studies are needed to understand the mechanisms leading to the increased VTE rate in KS. Moreover, an investigation into the relationship between TT and VTE is warranted to weigh the benefits of TT in VTE-prone patient groups like KS. Educational materials, such as a patient information pamphlet distributed in clinics and via associations like the UK’s KSA, are also needed to enhance awareness amongst KS patients of their VTE risk and potentially increased risk with TT.



4 thoughts on “Increased risk of Venous Thrombosis in XXY/KS further exacerbated by testosterone therapy

  1. This is important information. Sadly there is very little research about sideeffects by using testosteronproducts. Everyone gets the same even if you are young or old.


    1. All we can do is err on the side of caution and raise our concerns with a doctor who will hopefully take this information on board. Mind you, and this is especially so of XXY’s on high levels of T, I doubt if many of those would agree with a doctor telling them to lower the dose?


    1. I well understand the principle of DHEA but it is my understanding those with primary hypogonadism do not benefit from it because in most instances the testes are redundant and this is especially true of those who are administering exogenous T. So to answer your question we can only surmise, it being the United Kingdom and how so few delivery methods of T are bio-identical that the hormones in this instance were synthetic


Comments are closed.